TIME for a successful cancer vaccine in NSCLC?

Investigators of two phase 3 trials1,2 of nivolumab, a monoclonal antibody against PD-1, for second-line treatment of advanced non-small-cell lung cancer have reported significant improvements in overall survival and the proportion of patients achieving a response compared with standard cytotoxic ch...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-02, Vol.17 (2), p.131-132
Hauptverfasser:	Butts, Charles A, Sangha, Randeep
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Cancer vaccines Cancer Vaccines - therapeutic use Carcinoma, Non-Small-Cell Lung - therapy Chemotherapy Cytokines Dendritic cells Fees & charges Female Hematology, Oncology and Palliative Medicine Humans Immunotherapy Lung cancer Lung Neoplasms - therapy Lymphocytes Lymphocytes - chemistry Male Membrane Glycoproteins - therapeutic use Monoclonal antibodies Non-small cell lung carcinoma Pharmaceutical industry T cell receptors Targeted cancer therapy Vaccines Vectors (Biology)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!